Hinge Health Inc. Class A Common Stock (HNGE)

FairStock Score: 28/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses that earn consistent profits and trade at a sensible price. Hinge Health is not yet that, but the latest figures show improvement. Revenue in fiscal Q2 2026, the quarter ended 2026-06-30, was $212.8M, up from $139.1M in fiscal Q2 2025, the quarter ended 2025-06-30. Net income was $43.7M in fiscal Q2 2026, the quarter ended 2026-06-30, and $35.1M in fiscal Q1 2026, the quarter ended 2026-03-31, after a fiscal Q2 2025 net loss of $575.7M. The company has low debt, with D/E 0.02, trailing free cash flow of $283.9M, a Piotroski F-Score of 8/9, and an Altman Z-Score of 9.90. Those are real positives. But history matters. FY2023 net income was -$108.1M, FY2024 was -$11.9M, and FY2025 was -$528.3M. FairStock gives no Lynch category because it lost money in each of the last three years. At the 2026-10-13 close of $105.14, FairStock calculates a P/E of 12.79 but a P/B of 24.51. The Graham Number is $28.17, implying a margin of safety of -273.23%. EV/EBITDA is 86.30, and FCF yield is 3.2%. PEG is 0.12, but that depends on forward growth assumptions and a short profit record. The FairStock Score is 28/100. A moat may come from its technology platform and employer relationships, but the figures do not yet prove durable pricing power. I would want several more profitable quarters before trusting the current earnings. The price already discounts much of the recovery.

In plain English: Hinge Health sells technology-based muscle and joint care to employers, including an app, motion tracking, and a wearable device. The business is growing quickly and turned profitable in the first half of 2026, but it lost money in each of the last three full years. At $105.14 on 2026-10-13, the price looks rich compared with the company's stated net assets and past losses, even though recent profits make the picture mixed rather than clearly cheap.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer